摘要
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hypoglycemia or weight gain should be considered, also, whenever initial therapy is failed. There are many recent updates in the treatment paradigm of T2DM. There are many types of GLP-1RAs, with a knowledge gap regarding switching between the different types. A Saudi task force gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why, and how? This article contains the expert panel’s recommendations as a contribution to complement the knowledge gap in this area from the national perspective. As an alternative to intensifying therapy, switching from one GLP-1RA to another has various advantages. Improvements in glycemic control, weight loss, adherence, and medications with established cardiovascular benefits are among them. Also, switching needs to be individualized upon many discussed factors like the dose of the previous GLP1-RA and gastrointestinal adverse effects. Discussion with patients about the why and how to switch is critical.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hypoglycemia or weight gain should be considered, also, whenever initial therapy is failed. There are many recent updates in the treatment paradigm of T2DM. There are many types of GLP-1RAs, with a knowledge gap regarding switching between the different types. A Saudi task force gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why, and how? This article contains the expert panel’s recommendations as a contribution to complement the knowledge gap in this area from the national perspective. As an alternative to intensifying therapy, switching from one GLP-1RA to another has various advantages. Improvements in glycemic control, weight loss, adherence, and medications with established cardiovascular benefits are among them. Also, switching needs to be individualized upon many discussed factors like the dose of the previous GLP1-RA and gastrointestinal adverse effects. Discussion with patients about the why and how to switch is critical.
作者
Saud Alsifri
Hussein Elbadawi
Fahad Alsabaan
Abdulraouf Almahfouz
Khalid Alyahya
Eman Shesha
Laila Abu Esba
Meshal Alnais
Raed Aldahash
Turky Alharbi
Saleh Aljaser
Emad R. Issak
Saud Alsifri;Hussein Elbadawi;Fahad Alsabaan;Abdulraouf Almahfouz;Khalid Alyahya;Eman Shesha;Laila Abu Esba;Meshal Alnais;Raed Aldahash;Turky Alharbi;Saleh Aljaser;Emad R. Issak(Endocrinology Department, Alhada & Taif Armed Forces Hospitals, Taif, Saudi Arabia;My Clinic Medical Center, Jeddah, Saudi Arabia;Endocrinology Department, Security Forces Hospital, Riyadh, Saudi Arabia;Section of Endocrinology Department of Medicine, The King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia;Pharmacy Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia;Diabetes Center, King Salman Hospital, Riyadh, Saudi Arabia;King Abdulaziz Medical City, Riyadh, Saudi Arabia;Internal Medicine and Diabetes, King Khalid Hospital, Hail, Saudi Arabia;Department of Medicine, King Abdulaziz Medical City National Guard, Riyadh, Saudi Arabia;Family Medicine Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia;King Saud bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia;Medicine Department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt)
